Inventors:
Khandan Keyomarsi - Houston TX, US
Nikki Delk - Houston TX, US
Kelly K. Hunt - Houston TX, US
Hannah Wingate - Humble TX, US
Elizabeth A. Mittendorf - Houston TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
Research Development Foundation - Carson City NV
International Classification:
A61K 39/395, A61P 35/00, A61K 31/566, A61K 31/553, G01N 33/577, A61K 31/4196
US Classification:
4241331, 435 723, 514383, 514177, 51421108
Abstract:
Methods are disclosed for predicting a patient response to anti-Her2 therapy or anti-aromatase therapy. In certain embodiments, the methods involve the identification of low molecular weight cyclin E (LMW-E) in cancers, such as breast cancer cells, as a predictive and prognostic marker. In further embodiments, LMW-E expression by a cancerous or pre-cancerous cell may be used to predict response to an aromatase inhibitor and/or CDK2 inhibitor, and determination of LMW-E expression may be used in the personalization of cancer therapies.